{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-070574","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.312901+00:00","generated_at":"2026-06-01T05:45:54.389700+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Geron receives FDA approval for RYTELO (imetelstat) in lower-risk MDS with transfusion-dependent anemia","bullets":["RYTELO approved for low-to-int-1 risk MDS with TD anemia requiring ≥4 RBC units/8 wks who failed/are ineligible for ESAs.","Phase 3 IMerge trial: 8-week RBC-TI 39.8% vs 15.0% placebo (p<0.001); 24-week RBC-TI 28.0% vs 3.3% (p<0.001).","Median RBC-TI duration ~1 year for 8-week responders; ~1.5 years for 24-week responders.","Most common Grade 3/4 adverse reactions: neutropenia (72%) and thrombocytopenia (65%), each lasting median <2 weeks.","Conference call with Geron management scheduled for 8am ET on June 7, 2024 to discuss the approval and launch."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-070574","json":"https://secwatch.observer/filing/0000950170-24-070574.json","markdown":"https://secwatch.observer/filing/0000950170-24-070574.md","text":"https://secwatch.observer/filing/0000950170-24-070574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017024070574/0000950170-24-070574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017024070574/gern-20240606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:45:54.389700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}